Today's pre-market stock movers: FDX, REV, BCS, KMX and more

Moomoo Breakfast USwrote a column06/24/2022 20:44

Gainers:

• $Ballys(BALY.US)$ +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)

• $Ferguson(FERG.US)$ +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)

• $Bausch Health(BHC.US)$ +3.3% (chairman resigns)

• $Sanofi(SNY.US)$ +3.2% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)

• $NerdWallet(NRDS.US)$ +3.2% (to acquire On The Barrelhead for $120 mln)

• $Emergent BioSolutions(EBS.US)$ +3.1% (receives FDA Acceptance of BLA for AV7909 Anthrax vaccine candidate)

• $Intellia Therapeutics(NTLA.US)$ +2.4% (Intellia Therapeutics and Regeneron Pharmaceuticals (REGN) announce additional "positive" interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate NTLA-2001)

• $FedEx(FDX.US)$ +2.4% (In reaction to earnings/guidance)

• $Biomarin Pharmaceutical(BMRN.US)$ +2.3% (confirms that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for its investigational gene therapy valoctocogene roxaparvovec for adults with severe hemophilia A)

• $Castle Biosciences(CSTL.US)$ +2.2% (announces study findings that evaluated DecisionDx-UM)

• $Barclays(BCS.US)$ +2.2% (acquires Kensington Mortgage Company)

• $Takeda Pharmaceutical(TAK.US)$ +1.9% (to succeed to the rights and obligations relating to Plasma-Derived Therapies and all other businesses of Nihon through an absorption-type company split)

• $Novartis AG(NVS.US)$ +1.8% (receives positive CHMP opinion for Scemblix a novel treatment for adult patients with chronic myeloid leukemia)

• $Rocket Lab(RKLB.US)$ +1.7% (prepares to launch CAPSTONE to the Moon)

• $Datadog(DDOG.US)$ +1.6% (launches Datadog Audit Trail)

• $Primoris Services(PRIM.US)$ +1.6% (receives $260 mln solar project award)

• $GlaxoSmithKline(GSK.US)$ +1.1% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)

• $Petroleo Brasileiro SA Petrobras(PBR.US)$ +1.1% (approved the sale of its total stake in the maritime concessions groups named Golfinho Cluster and Camarupim Cluster)

Analyst comments:

• $Aurora Cannabis(ACB.US)$ +4.2% (upgraded to Overweight from Neutral at Cantor Fitzgerald)

• $Becton Dickinson & Co(BDX.US)$ +1.2% (upgraded to Overweight from Equal Weight at Wells Fargo)

Losers:

• $CalAmp(CAMP.US)$ -16.4% (In reaction to earnings/guidance)

• $LendingTree(TREE.US)$ -6% (lowers Q2 rev guidance due to challenging interest rate environment),

• $Revlon(REV.US)$ -5.7% (discloses that a portion of the proceeds of the initial borrowing under the DIP Term Loan Facility were used to repay in full and terminate the Foreign ABL Credit Agreement)

• $Cytokinetics(CYTK.US)$ -1.2% (FDA to hold Adcomm for omecamtiv mecarbil on Dec. 13 2022)

• $Smith & Wesson Brands(SWBI.US)$ -1.7% (also increases dividend)

• $CarMax(KMX.US)$ -0.8% (In reaction to earnings/guidance)

• $Novavax(NVAX.US)$ -0.9% (receives EUA in Taiwan for its Nuvaxovid COVID-19 vaccine for 18+)

• $Sarepta Therapeutics(SRPT.US)$ -0.5% (FDA places clinical hold on SRP-5051 for Duchenne muscular dystrophy)

Analyst comments:

• $Baxter International Inc(BAX.US)$ -1.7% (downgraded to Equal Weight from Overweight at Wells Fargo)

• $Ameriprise Financial(AMP.US)$ -1.1% (downgraded to Neutral from Buy at Goldman)

Moomoo is an app offered by Moomoo Technologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

1 Comment · 397K Views

Comment

Report